News Releases

SHINE Signs $125M Term Sheet

October 10, 2014

SHINE Medical Technologies, Inc. (SHINE) announced today that it executed a term sheet providing for up to $125 million of debt and equity financing with Deerfield Management Company, L.P. (Deerfield), a New York headquartered healthcare investment firm. SHINE plans to build a new manufacturing plant in Wisconsin to produce more than a quarter of world supply of the most commonly-used isotope in nuclear medicine, molybdenum-99 (moly-99)...Read More

SHINE Medical and Phoenix Nuclear Achieve Key Technical Milestone

Phoenix Nuclear Labs
August 12, 2014

SHINE Medical Technologies and Phoenix Nuclear Labs (PNL) announced today that they successfully operated their second-generation neutron driver prototype for 24 consecutive hours with 99% uptime. Completion of this milestone is an important demonstration of the reliability and robustness of the PNL neutron driver, which is a key enabling technology for SHINE’s isotope production facility...Read More

SHINE to Hold Information Session

June 16, 2014

SHINE Medical Technologies, Inc. (SHINE Medical), a Wisconsin-based company dedicated to being the world leader in safe, clean, affordable production of medical isotopes and cancer treatment elements, announced today that it will present an update on its progress in the development and planning for its Janesville medical isotope facility on Wednesday, June 18th at the Holiday Inn Express, 3100 Wellington Place in Janesville...Read More

James L. Connaughton Joins SHINE

May 15, 2014

SHINE Medical Technologies, Inc. (SHINE), a Wisconsin-based company dedicated to being the world leader in safe, clean, affordable production of medical isotopes, announced today that James L. Connaughton has agreed to serve as a strategic advisor to management as SHINE continues its efforts to bring molybdenum-99 (moly-99) to market...Read More

SHINE to Supply Mo-99 to GE Healthcare

April 3, 2014

SHINE Medical Technologies, Inc. (SHINE), a Wisconsin‐based company dedicated to being the world leader in safe, clean, affordable production of medical isotopes, announced today that it has entered into a strategic long‐term supply agreement with GE Healthcare, a division of the General Electric Company, for supply of molybdenum‐99 (moly‐99)...Read More

SHINE Construction Permit Application Accepted by NRC

December 4, 2013

SHINE Medical Technologies, Inc. (SHINE), a Wisconsin-based company dedicated to being the world leader in safe, clean, affordable production of medical isotopes and cancer treatment elements, announced today that the Nuclear Regulatory Commission (NRC) has accepted for review the second half of SHINE’s construction permit application to build a medical isotope production plant near Janesville, WI...Read More

SHINE to Hold Information Session

City-Of-Janesville-Logo
November 26, 2013

SHINE updates the Janesville Community. ..Read More

NRC Dockets SHINE Construction Permit Application

US-NRC Logo
July 4, 2013

SHINE Medical Technologies, Inc. (SHINE), a Wisconsin-based company dedicated to being the world leader in safe, clean, and affordable production of medical isotopes and cancer treatment elements, has received notice that the Nuclear Regulatory Commission (NRC) has accepted the first part of its Construction Permit application for review and docketing. This is the first formal step by the NRC in the construction permitting process for the SHINE medical isotope facility in Janesville, Wisconsin...Read More

SHINE to Hold Information Session

City-Of-Janesville-Logo
June 5, 2013

SHINE Medical Technologies, Inc. (SHINE Medical), a Wisconsin-based company dedicated to being the world leader in safe, clean, affordable production of medical isotopes and cancer treatment elements, announced today that it will present an update on its progress in the development and planning for its Janesville medical isotope facility on Thursday, June 13th at the Holiday Inn Express, 3100 Wellington Place in Janesville...Read More

SHINE Files 2nd Part of NRC Construction Permit Application

PSAR
June 5, 2013

SHINE Medical Technologies, Inc. (SHINE), a Wisconsin-based company dedicated to being the world leader in safe, clean, and affordable production of medical isotopes and cancer treatment elements, has submitted the remaining chapters of its Construction Permit application to the Nuclear Regulatory Commission (NRC)...Read More

Los Alamos Team Produces Mo-99 From Irradiation of LEU Solution

Los-Alamos-National-Labboratory-Logo
May 14, 2013

Today, Los Alamos National Laboratory announced that for the first time, irradiated low-enriched uranium (LEU) fuel has been recycled and reused for molybdenum-99 (Mo-99) production, with virtually no losses in Mo-99 yields or uranium recovery...Read More

SHINE Meets Major Milestone in Medical Isotope Production Effort

May 2, 2013

SHINE Medical Technologies (SHINE) announced today that its development program with Phoenix Nuclear Labs (PNL) reached an important technical milestone by successfully producing 3x1011 neutrons per second with the deuterium-deuterium fusion reaction. ..Read More